Atara Biotherapeutics Inc (ATRA) Shares Traded Up 12% Following Strong Revenue

Remigio Civitarese
Aprile 17, 2018

(TSE:VRX) has 0.00% since April 13, 2017 and is. It has underperformed by 25.74% the S&P500. Russell Investments Group Ltd. purchased a new position in Atara Biotherapeutics during the third quarter valued at $170,000. Insiders now own 4.40% of the 44.71 total outstanding shares. Its down 7.26% from 5.19 million shares previously. Redmile Gp Ltd has invested 2.22% of its capital in Atara Biotherapeutics, Inc. The stock decreased 3.79% or $1.6 during the last trading session, reaching $40.6. About 345,457 shares traded. On Monday, October 16 Haqq Christopher sold $86,100 worth of Atara Biotherapeutics, Inc. ATRA outperformed by 77.18% the S&P500. This is based on a 1-5 numeric scale where Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell. Therefore 60% are positive. Atara Biotherapeutics had 11 analyst reports since December 29, 2017 according to SRatingsIntel. JMP Securities initiated the stock with "Mkt Perform" rating in Friday, September 25 report. Alps Advisors Inc. now owns 33,904 shares of the biotechnology company's stock valued at $614,000 after purchasing an additional 3,809 shares in the last quarter. (NASDAQ:ATRA) rating. Canaccord Genuity has "Buy" rating and $70.0 target. The company was upgraded on Monday, November 7 by KeyBanc Capital Markets. On Monday, October 24 the stock rating was reinitiated by Jefferies with "Buy". On Friday, April 6 the firm has "Buy" rating by William Blair given. The firm has "Sell" rating given on Thursday, February 15 by Citigroup. On Wednesday, January 3 the company was upgraded by Citigroup. Finally, Canaccord Genuity restated a buy rating and set a $70.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, March 13th. The firm is scheduled to announce its next quarterly earnings results on Thursday, May 3rd.

Since October 11, 2017, it had 0 insider buys, and 20 sales for $14.24 million activity. Ciechanover Isaac E. had sold 1,000 shares worth $46,314. $3.80M worth of stock was sold by Clark Mitchall G. on Tuesday, March 27. Zacks' EPS averages are an average based on a survey of research analysts that cover Atara Biotherapeutics. 12,214 shares valued at $464,210 were sold by Turner Heather D on Friday, February 9. (NASDAQ:ATRA). Metropolitan Life Insurance stated it has 9,283 shares or 0% of all its holdings. Shares for $55,010 were sold by Gallagher Carol Giltner. (NASDAQ:ATRA) on Wednesday, September 9 with "Buy" rating.

Big Money Sentiment decreased to 1.42 in 2017 Q4. 158,422 shares of the stock were exchanged, compared to its average volume of 1,084,020.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 48,500 shares of the business's stock in a transaction dated Wednesday, January 24th. Dimensional Fund Advisors LP grew its stake in shares of Atara Biotherapeutics by 2.9% during the 2nd quarter. Rhumbline Advisers has 0% invested in Atara Biotherapeutics, Inc. Goldman Sachs Gru invested in 0% or 20,266 shares. Wells Fargo Company Mn invested 0% in Atara Biotherapeutics, Inc.

Analysts expect Atara Biotherapeutics, Inc. BidaskClub raised shares of Atara Biotherapeutics from a "hold" rating to a "buy" rating in a report on Thursday, January 11th. (NASDAQ:ATRA). 1.96 million are held by Blackrock. Guggenheim assumed coverage on Atara Biotherapeutics in a research report on Thursday, March 15th. Citigroup Inc owns 229 shares or 0% of their USA portfolio. Schwab Charles Incorporated accumulated 0% or 104,612 shares. It is negative, as 0 investors sold ITT Inc. shares while 0 reduced holdings. (NASDAQ:ATRA). Vident Inv Advisory Lc owns 85,810 shares. Thompson Davis Co Inc holds 0% or 125 shs. (NASDAQ:ATRA) for 1.49M shares. 27,740 are owned by Alliancebernstein L P. State Street Corp holds 0% or 443,821 shs in its capital.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The Company's clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE